2 August 2016 - In order to help ensure the accuracy of Medicare Part B drug payment rates, the US Government Accountability Office on Monday urged Congress to require all manufacturers of Part B drugs paid at average sales price to submit sales price data to the Centers for Medicare & Medicaid Services.

What’s more, Government Accountability Office is calling on Congress to ensure that Centers for Medicare & Medicaid Services (CMS) has the authority to request source documentation to periodically validate drug companies’ pricing data, which will likely be a sore issue for pharmaceutical companies as only manufacturers with Medicaid drug rebate agreements are currently required to submit sales price data to CMS.

Read Regulatory Affairs Professional Society article